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INTRODUCTION
The first outbreaks in Poland of viral haemorrhagic disease (VHD), an acute and fatal infectious disease of rabbits, were recognised in the regions of Krakow and Silesia in the south of the country in spring 1988 (9) . A similar disease affecting rabbits had been reported in 1987 in Slovakia and Ukraine (23, 24, 27) . In 1988, the spread of the infection in Poland was very rapid, with high morbidity and mortality. The Ministry of Agriculture therefore included VHD on the national list of notifiable diseases. The first vaccination attempts were made in autumn 1988, and large-scale production of the commercial inactivated vaccine developed at the National Veterinary Research Institute (NVRI) began in 1989.
MATERIALS AND METHODS

Epizootiological analysis
The number of outbreaks, numbers of dead or slaughtered rabbits and the territorial range of VHD were based on reports of infectious diseases issued by the Veterinary Service of the Ministry of Agriculture. Data concerning vaccine production were obtained from the NVRI.
Virus
The following strains of VHD virus were isolated from internal organs of animals which died during outbreaks: SGM, KGM, PD and ZW (7, 9) . Viruses were stored as 20% homogenates or freeze-dried at -18°C and 4°C.
Estimation of virus titre
The haemagglutination (HA) titre of VHD virus strains was determined using human erythrocytes. The 50% lethal dose (LD 50 ) of this virus was also evaluated.
Serological tests
All serological data were obtained by the haemagglutination inhibition (HI) test (7, 20, 28) .
Animals
Experiments were performed on New Zealand and California breeds, and cross-bred rabbits of various ages and weights, mostly 2.0-3.0 kg. Rabbits were infected with VHD virus by the subcutaneous, intramuscular, intraperitoneal, intracerebral, oral and intranasal routes. In some experiments, other animals (dogs, cats, guinea-pigs, mice, blue foxes and hares) were also used.
Post-mortem examination and sampling
All the animals, both dead animals and those which survived experimental infection, were subjected to necropsy. Internal organs were sampled for use in histopathological and electron microscopic examination, and in the HA test.
Electron microscopy
Ultra-thin sections were prepared and stained according to the method described by Reynolds (22) . The sections were examined and photographed at a magnification ranging from 8,000x to 62,000x.
Chemical properties
Resistance of the virus to ether (1) and chloroform (2) was examined. The inactivating properties of formalin, biethylenoimine (BEI), ethyl alcohol, sodium hydroxide (NaOH), iodine in Pollena JK and potassium persulfate in Virkon-Naturan were tested at various temperatures, using different concentrations of chemicals and times of inactivation.
Vaccine tests
'Cunivac', a vaccine against VHD virus, was tested for sterility, safety, level of virus inactivation and efficacy (10) .
Calculation of results
LD 50 titres were calculated by the method described by Reed and Münch (21) . HA and HI titres were expressed as a reciprocal of the highest dilution. Means were presented as x (arithmetic) and x g (geometric).
RESULTS
Occurrence and spread of viral haemorrhagic disease in Poland
In contrast to myxomatosis (12) , VHD is characterised by rapid territorial spread. The first two outbreaks of the disease in Poland were recognised in April 1988 and, by the end of the year, 865 outbreaks and a total of 27,752 dead rabbits in 18 regions had been reported (Figs 1 and 2 ). The mortality rate following natural infection was variable, ranging from a few cases to 99.5% losses. The highest mortality was observed in Angora rabbits and cross-breeds. At first, only adult rabbits were affected, while young animals became ill one to three weeks later. On one farm with 200 rabbits, 199 died within 15 days, showing typical signs (9, 15, 17) . The highest mortality rate was noted between 7 and 12 days after the appearance of the first clinical symptoms. An acute form of VHD was observed after parenteral inoculation. Of 481 rabbits, 3 died before 18 h post-inoculation (p.i.), 31 between 18 and 24 h p.i., 273 between 38 and 56 h, 35 after approximately 72 h, and 9 animals after 96 h p.i. There were no differences in the timing of the occurrence of the first clinical signs in rabbits infected by various routes.
Epizootiological analysis revealed that rabbits are not the only source of infection. The transport of infected animals, meat or objects may also have spread the infection.
Seasonal prevalence of the disease is presented in Figure 3 . The greatest number of outbreaks occurs during the summer. This was observed both in 1988 and in the following years. The decline in the number of outbreaks is shown in Figures 1 and 2 .
CHARACTERISTICS OF THE POLISH VACCINE AGAINST VIRAL HAEMORRHAGIC DISEASE
The positive results achieved by other investigators (13, 29) encouraged the preparation of a Polish vaccine. Replication of the native isolates in various cell cultures proved impossible, and internal organs of experimentally-infected rabbits were therefore used as a source of antigen. Both transmissible clinical symptoms and morphological changes in tissues of rabbits were noted after experimental infection. These were similar to those described by other authors (15, 24, 27, 31) . The titre of the virus in liver homogenates was equal to 10 30 -10 60 ID 50 , and HA titres ranged from 1/160 to 1/10,240. Results were repeatable.
As shown in Table I (11, 17, 24) . Long-term stability is typical of VHD virus. The virus may survive for 51 months at -18°C, over 50 months at 4°C and 10-19 months when kept at room temperature. The KGM and SGM strains were resistant to ether, chloroform and pH 3. The virus was not inactivated after exposure for 2 h to 2% Virkon, 3% Pollena JK and 70% ethanol (8) . The following were infallible inactivators of the virus: 0.2% formaline (24 h at 37°C), 0.4% BEI, 1% NaOH and 4% Virkon. The agglutination properties of the virus were not affected by the above disinfectants. The KGM, SGM, PD and ZW strains were apathogenic for suckling and adult mice, and guinea-pigs. KGM and SGM were also apathogenic for hares, dogs, cats and blue foxes (17) .
Determination of the conditions for viral replication and inactivation, the physicochemical and biological properties of the virus, and methods of virus purification (11) enabled preparation of the vaccine. In 1988, five experimental batches of the inactivated, gel-adjuvanted vaccine were prepared. The tests for sterility, safety and efficacy were satisfactory and the vaccine was comparable to that produced in Czechoslovakia (23, 26) . Experimental and reference vaccines were used for 66 rabbits. All the animals remained healthy and survived challenge. Field observations were performed on 604 rabbits which remained healthy for over six months (10) . In 1989, large-scale production of Cunivac began at the NVRI, and 765,200 doses (13 batches) had been produced by 1993. All 128 vaccinated rabbits remained resistant to challenge, while 87 of 108 controls died. Further investigations indicated that immunity was developed as early as four days after vaccination. Rabbits were also resistant to challenge when vaccinated with 1 ml of the vaccine as well as with 0.5 ml and 0.1 ml.
The immunogenic properties of the vaccine were shown after 27 months of storage at 4°C, and 50% of rabbits were immune when vaccinated with Cunivac stored at 4°C for 31 months (A. Fitzner, unpublished findings). The expiry date of the vaccine is 18 months from the date of production.
The efficacy of prophylactic vaccination was confirmed by veterinary practitioners. The use of the vaccine in a contaminated area did not reduce mortality in rabbits. However, the mortality rate decreased to 31% on one infected farm where rabbits were kept in separate buildings.
Dynamics of haemagglutination (HA) titre in rabbits infected with viral haemorrhagic disease virus
SIMULTANEOUS VACCINATION AGAINST MYXOMATOSIS AND VIRAL HAEMORRHAGIC DISEASE
Ten rabbits were vaccinated simultaneously against myxomatosis and VHD, using 'Myxovac M' and Cunivac. All vaccinated rabbits remained healthy and gained weight throughout the 21-day observation period, together with twelve rabbits which were vaccinated only with Myxovac M or Cunivac. Challenge with virulent KGM and ZA strains (VHD and myxomatosis virus, respectively) was performed in two separate rooms. Results are presented in Table III . 
DIAGNOSIS AND CONTROL OF VHD
Diagnosis of VHD is based on clinical and epidemiological observations, as well as pathological examinations. Other tests -HA test using human erythrocytes, immunofluorescence, immunoprecipitation and inoculation of rabbits -are also used in laboratory diagnosis to confirm infection with VHD virus.
Legal regulations for VHD are the same as those which apply for myxomatosis (12) .
DISCUSSION
The rapid spread and clinical course of VHD in Poland were similar to those described in other countries (4, 14, 18, 23) . Laboratories using rabbits for diagnosis, and for the production and control of biological preparations and drugs, suffered heavy losses due to VHD. The largest number of outbreaks was reported in 1988, followed by significant regression. Between 1988 and 1990, the number of outbreaks in Germany increased (14) . Experimental inoculation of different species revealed that only rabbits were susceptible to this virus infection. None of 21 infected hares showed clinical symptoms of VHD, and no virus was detected in the internal organs of these animals for 21 days after challenge. VHD and European brown hare syndrome are caused by antigenically similar viruses, but cross-infection between rabbits and hares does not occur (3, 4, 5, 6, 19, 26) . The high resistance of VHD virus to physico-chemical factors was confirmed by other research workers (26, 30, 31) . The present study revealed long viability of the virus and low efficacy of some of the disinfectants used. The use of human erythrocytes of all types -not only O (20) -for the diagnosis of VHD was also demonstrated (7).
The use of efficacious Polish vaccine against VHD reduced the economic losses in the rabbit population. Rabbits developed immunity as soon as four days after vaccination with Cunivac, confirming the reports of Smid et al. (26) and Huang (13) . Preliminary observations indicated that simultaneous vaccination with Myxovac M and Cunivac, together with elimination of biological vectors, is an effective method for the control of both myxomatosis and VHD in Poland.
CONCLUSION
A number of factors -the experimental work which has been performed, the efforts of the Veterinary Services, increased familiarity with the problem among breeders (through publications), the improvement of diagnostic methods, and the use of safe and efficacious vaccines -have all contributed to a reduction of the economic losses caused by myxomatosis and VHD in Poland. 
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